Mr. Antony Mattesich is an experienced biotech leader with over 30 years’ experience in the life science industry. He has an impressive track record in progressing programs from discovery, through clinical development and commercial success, and strong capital markets experience. He has held several senior executive positions where he was instrumental in developing medicines that translate innovative science into meaningful clinical outcomes for patients, with extensive experience in CNS, haemato-oncology, immunology, and metabolics. He is currently CEO of Amphista Therapeutics. Prior to Amphista, he was President and CEO of Nasdaq-listed Ocular Therapeutix (OCUL), where he launched the company’s lead asset and brought its potential blockbuster in Wet Age-Related Macular Degeneration (wet-AMD) from pre-clinical development into active enrollment in Phase 3. Prior to Ocular, he was Managing Director of Mundipharma and has held senior positions at Novartis and Bristol-Myers Squibb. He holds a BA from the University of California at Berkeley and a Masters in International affairs from Columbia University.
Board of Directors